Clinical and Pathological Characterization of Lynch-Like Syndrome.


Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775

Informations de publication

Date de publication:
02 2020
Historique:
received: 21 03 2019
revised: 20 05 2019
accepted: 07 06 2019
pubmed: 21 6 2019
medline: 19 8 2021
entrez: 21 6 2019
Statut: ppublish

Résumé

Lynch syndrome is characterized by DNA mismatch repair (MMR) deficiency. Some patients with suspected Lynch syndrome have DNA MMR deficiencies but no detectable mutations in genes that encode MMR proteins-this is called Lynch-like syndrome (LLS). There is no consensus on management of patients with LLS. We collected data from a large series of patients with LLS to identify clinical and pathology features. We collected data from a nationwide-registry of patients with colorectal cancer (CRC) in Spain. We identified patients whose colorectal tumors had loss of MSH2, MSH6, PMS2, or MLH1 (based on immunohistochemistry), without the mutation encoding V600E in BRAF (detected by real-time PCR), and/or no methylation at MLH1 (determined by methylation-specific multiplex ligation-dependent probe amplification), and no pathogenic mutations in MMR genes, BRAF, or EPCAM (determined by DNA sequencing). These patients were considered to have LLS. We collected data on demographic, clinical, and pathology features and family history of neoplasms. The χ We identified 160 patients with LLS; their mean age at diagnosis of CRC was 55 years and 66 patients were female (41%). The Amsterdam I and II criteria for Lynch syndrome were fulfilled by 11% of cases and the revised Bethesda guideline criteria by 65% of cases. Of the patients with LLS, 24% were identified in universal screening. There were no proportional differences in sex, indication for colonoscopy, immunohistochemistry, pathology findings, or personal history of CRC or other Lynch syndrome-related tumors between patients who met the Amsterdam and/or Bethesda criteria for Lynch syndrome and patients identified in universal screening for Lynch syndrome, without a family history of CRC. Patients with LLS have homogeneous clinical, demographic, and pathology characteristics, regardless of family history of CRC.

Sections du résumé

BACKGROUND & AIMS
Lynch syndrome is characterized by DNA mismatch repair (MMR) deficiency. Some patients with suspected Lynch syndrome have DNA MMR deficiencies but no detectable mutations in genes that encode MMR proteins-this is called Lynch-like syndrome (LLS). There is no consensus on management of patients with LLS. We collected data from a large series of patients with LLS to identify clinical and pathology features.
METHODS
We collected data from a nationwide-registry of patients with colorectal cancer (CRC) in Spain. We identified patients whose colorectal tumors had loss of MSH2, MSH6, PMS2, or MLH1 (based on immunohistochemistry), without the mutation encoding V600E in BRAF (detected by real-time PCR), and/or no methylation at MLH1 (determined by methylation-specific multiplex ligation-dependent probe amplification), and no pathogenic mutations in MMR genes, BRAF, or EPCAM (determined by DNA sequencing). These patients were considered to have LLS. We collected data on demographic, clinical, and pathology features and family history of neoplasms. The χ
RESULTS
We identified 160 patients with LLS; their mean age at diagnosis of CRC was 55 years and 66 patients were female (41%). The Amsterdam I and II criteria for Lynch syndrome were fulfilled by 11% of cases and the revised Bethesda guideline criteria by 65% of cases. Of the patients with LLS, 24% were identified in universal screening. There were no proportional differences in sex, indication for colonoscopy, immunohistochemistry, pathology findings, or personal history of CRC or other Lynch syndrome-related tumors between patients who met the Amsterdam and/or Bethesda criteria for Lynch syndrome and patients identified in universal screening for Lynch syndrome, without a family history of CRC.
CONCLUSIONS
Patients with LLS have homogeneous clinical, demographic, and pathology characteristics, regardless of family history of CRC.

Identifiants

pubmed: 31220642
pii: S1542-3565(19)30650-0
doi: 10.1016/j.cgh.2019.06.012
pii:
doi:

Substances chimiques

MutL Protein Homolog 1 EC 3.6.1.3

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

368-374.e1

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

Auteurs

María Dolores Picó (MD)

Servicio de Medicina Digestiva, Hospital General Universitario de Elche, Elche, Alicante, Spain.

Adela Castillejo (A)

Unidad de Genética Molecular, Hospital General Universitario de Elche, Alicante, Spain.

Óscar Murcia (Ó)

Servicio de Medicina Digestiva. Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria ISABIAL, Alicante, Spain.

Mar Giner-Calabuig (M)

Servicio de Medicina Digestiva. Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria ISABIAL, Alicante, Spain.

Miren Alustiza (M)

Servicio de Medicina Digestiva. Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria ISABIAL, Alicante, Spain.

Ariadna Sánchez (A)

Unidad de Gastroenterología, Hospital Clínic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain.

Leticia Moreira (L)

Unidad de Gastroenterología, Hospital Clínic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain.

María Pellise (M)

Unidad de Gastroenterología, Hospital Clínic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain.

Antoni Castells (A)

Unidad de Gastroenterología, Hospital Clínic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain.

Marta Carrillo-Palau (M)

Servicio de Medicina Digestiva, Hospital Universitario de Canarias, Tenerife, Spain.

Teresa Ramon Y Cajal (T)

Servicio de Medicina Digestiva, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Alexandra Gisbert-Beamud (A)

Servicio de Medicina Digestiva, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Gemma Llort (G)

Servicio de Oncología Médica, Parc Taulí, Hospital Universitari Parc Taulí, Sabadell, Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain.

Carmen Yagüe (C)

Servicio de Oncología Médica, Parc Taulí, Hospital Universitari Parc Taulí, Sabadell, Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain.

Adriá López-Fernández (A)

Unidad de Alto Riesgo y Prevención del Cáncer, Hospital Universitario Vall d'Hebron, Barcelona, Spain.

Cristina Alvarez-Urturi (C)

Servicio de Medicina Digestiva, Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.

Joaquin Cubiella (J)

Departamento de Gastroenterología, Complexo Hospitalario Universitario de Ourense, Instituto de Investigación Sanitaria Galicia Sur, CIBERehd, Ourense, Spain.

Laura Rivas (L)

Departamento de Gastroenterología, Complexo Hospitalario Universitario de Ourense, Instituto de Investigación Sanitaria Galicia Sur, CIBERehd, Ourense, Spain.

Daniel Rodríguez-Alcalde (D)

Sección de Aparato Digestivo, Hospital Universitario de Móstoles, Móstoles, Spain.

Maite Herraiz (M)

Departamento de Digestivo, Clínica Universitaria de Navarra, Navarra, Spain.

Catalina Garau (C)

Servicio de Medicina Digestiva, Hospital de Son Llàtzer, Palma de Mallorca, Spain.

Carlos Dolz (C)

Servicio de Medicina Digestiva, Hospital de Son Llàtzer, Palma de Mallorca, Spain.

Luis Bujanda (L)

Hospital Donostia/Instituto Biodonostia, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd). Universidad del País Vasco (UPV/EHU), San Sebastián, Spain.

Lucia Cid (L)

Servicio de Medicina Digestiva, Hospital Álvaro Cunqueiro de Vigo, Vigo, Spain.

Carmen Povés (C)

Servicio de Medicina Digestiva, Hospital Clínico de San Carlos, Madrid, Spain.

Marta Garzon (M)

Servicio de Medicina Digestiva, Hospital Universitario Virgen del Rocío, Sevilla, Spain.

Inmaculada Salces (I)

Servicio de Medicina Digestiva, Hospital 12 de Octubre, Madrid, Spain.

Marta Ponce (M)

Servicio de Medicina Digestiva, Hospital Universitari i Politècnic de la Fe, Valencia, Spain.

Luís Hernández-Villalba (L)

Sección de Aparato Digestivo, Hospital Santos Reyes, Aranda del Duero, Spain.

Cristina Alenda (C)

Servicio de Anatomía Patológica, Hospital General Universitario de Alicante, Alicante, Spain.

Francesc Balaguer (F)

Unidad de Gastroenterología, Hospital Clínic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain.

Jose-Luis Soto (JL)

Unidad de Genética Molecular, Hospital General Universitario de Elche, Alicante, Spain.

Rodrigo Jover (R)

Servicio de Medicina Digestiva. Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria ISABIAL, Alicante, Spain. Electronic address: rodrigojover@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH